Contineum Therapeutics Statistics
Total Valuation
CTNM has a market cap or net worth of $519.92 million. The enterprise value is $289.95 million.
| Market Cap | 519.92M |
| Enterprise Value | 289.95M |
Important Dates
The next estimated earnings date is Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CTNM has 37.62 million shares outstanding. The number of shares has increased by 29.38% in one year.
| Current Share Class | 32.96M |
| Shares Outstanding | 37.62M |
| Shares Change (YoY) | +29.38% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 0.84% |
| Owned by Institutions (%) | 68.55% |
| Float | 27.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 103.98 |
| PB Ratio | 2.17 |
| P/TBV Ratio | 2.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 37.17, with a Debt / Equity ratio of 0.03.
| Current Ratio | 37.17 |
| Quick Ratio | 36.25 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.01% and return on invested capital (ROIC) is -652.37%.
| Return on Equity (ROE) | -28.01% |
| Return on Assets (ROA) | -19.15% |
| Return on Invested Capital (ROIC) | -652.37% |
| Return on Capital Employed (ROCE) | -27.22% |
| Weighted Average Cost of Capital (WACC) | 8.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.13M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.86% in the last 52 weeks. The beta is 0.75, so CTNM's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | +11.86% |
| 50-Day Moving Average | 15.30 |
| 200-Day Moving Average | 13.61 |
| Relative Strength Index (RSI) | 36.47 |
| Average Volume (20 Days) | 397,449 |
Short Selling Information
The latest short interest is 2.34 million, so 6.22% of the outstanding shares have been sold short.
| Short Interest | 2.34M |
| Short Previous Month | 2.34M |
| Short % of Shares Out | 6.22% |
| Short % of Float | 8.41% |
| Short Ratio (days to cover) | 4.20 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -66.38M |
| Pretax Income | -57.56M |
| Net Income | -57.56M |
| EBITDA | -66.00M |
| EBIT | -66.38M |
| Earnings Per Share (EPS) | -$1.72 |
Balance Sheet
The company has $236.55 million in cash and $6.57 million in debt, with a net cash position of $229.98 million or $6.11 per share.
| Cash & Cash Equivalents | 236.55M |
| Total Debt | 6.57M |
| Net Cash | 229.98M |
| Net Cash Per Share | $6.11 |
| Equity (Book Value) | 239.66M |
| Book Value Per Share | 6.37 |
| Working Capital | 236.05M |
Cash Flow
In the last 12 months, operating cash flow was -$53.01 million and capital expenditures -$458,000, giving a free cash flow of -$53.46 million.
| Operating Cash Flow | -53.01M |
| Capital Expenditures | -458,000 |
| Depreciation & Amortization | 383,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -53.46M |
| FCF Per Share | -$1.42 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CTNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.38% |
| Shareholder Yield | -29.38% |
| Earnings Yield | -11.07% |
| FCF Yield | -10.28% |
Analyst Forecast
The average price target for CTNM is $23.43, which is 69.54% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.43 |
| Price Target Difference | 69.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |